bb 2121

Drug Profile

bb 2121

Alternative Names: Anti-BCMA CART cells - bluebird bio/Celgene; BB2121

Latest Information Update: 20 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator bluebird bio
  • Developer bluebird bio; Celgene Corporation
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple myeloma

Most Recent Events

  • 30 Jul 2018 Celgene Corporation plans a phase II KarMMa-2 trial for Multiple myeloma (Second-line therapy or greater) in October 2018 (NCT03601078) (EudraCT2018-000264-28)
  • 01 Jun 2018 Updated efficacy and safety data from the phase I CRB-401 trial in Multiple myeloma released by Celgene Corporation
  • 09 Apr 2018 bluebird bio announces intention to submit BLA to the US FDA for Multiple myeloma (Refractory metastatic disease, Second-line therapy or greater) in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top